Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Evaluating Periconception Exposure and Perinatal Outcomes
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Evaluating Periconception Exposure and Perinatal Outcomes

GLP-1 receptor agonists are increasingly used in women of reproductive age, but their safety during periconception and pregnancy remains unclear. Current observational data show no definitive harm, yet robust evidence is lacking, emphasizing individualized counseling and further research.
Navigating Prolactinomas in Pregnancy: An Evidence-Based Approach for Optimal Maternal and Fetal Outcomes
Posted inDiabetes & Endocrinology news OB/GYN & Women’s Health

Navigating Prolactinomas in Pregnancy: An Evidence-Based Approach for Optimal Maternal and Fetal Outcomes

Prolactinomas, common pituitary adenomas in reproductive-age women, challenge pregnancy management due to risks of tumor growth and hormonal shifts. This article reviews current strategies for diagnosis, treatment, and monitoring before, during, and after pregnancy to ensure safety and fertility restoration.
Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study

A French nationwide cohort study finds first-trimester exposure to second-line glucose-lowering agents, including GLP-1 receptor agonists, is generally safe for pregnancies with type 2 diabetes, though a slight increase in cardiac malformations cannot be excluded.
Bridging the Gap: Advancing Automated Insulin Delivery for Pregnant Women with Type 1 Diabetes
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Bridging the Gap: Advancing Automated Insulin Delivery for Pregnant Women with Type 1 Diabetes

Automated insulin delivery (AID) systems, while transformative for type 1 diabetes management, currently lack pregnancy-specific adaptations, leaving a critical gap in care. This article highlights the urgent need to include pregnant women in AID research and develop pregnancy-optimized systems to improve maternal and perinatal outcomes.
Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study

This study reveals that polyendocrine metabolic ovarian syndrome (PMOS) during pregnancy increases risks of early gestational diabetes and adverse neonatal outcomes, underscoring the need for timely identification and management to improve maternal-fetal health.
Psychostimulant Continuation and Postpartum Mental Health in Pregnant People With Attention-Deficit/Hyperactivity Disorder: A Clinical Evidence Review
Posted inClinical Updates news OB/GYN & Women's Health Psychiatry

Psychostimulant Continuation and Postpartum Mental Health in Pregnant People With Attention-Deficit/Hyperactivity Disorder: A Clinical Evidence Review

This review synthesizes current evidence on the impact of continuing psychostimulant treatment during pregnancy on postpartum mental health outcomes among people with ADHD, highlighting key findings and clinical implications from recent large-scale cohort research.
Ebola Virus in Pregnancy: Current Insights and Clinical Implications During the DR Congo Outbreak
Posted inInfectious Diseases news OB/GYN & Women’s Health

Ebola Virus in Pregnancy: Current Insights and Clinical Implications During the DR Congo Outbreak

This article reviews updated clinical understanding of Ebola virus disease in pregnancy amid the Democratic Republic of Congo outbreak, highlighting maternal outcomes, risks of vertical transmission, treatment challenges, and the critical need for inclusion of pregnant individuals in therapeutic trials.